Medivir presents the first clinical data with fostrox + Lenvima at the ASCO GI scientific congress, showing further improved clinical benefit vs previous interim updates from the ongoing phase Ib/IIa study in advanced hepatocellular carcinoma. According to the company, the data supports the planning for a pivotal phase IIb study in 2024. BioStock reached out to Pia Baumann, Medivir's CMO, to learn more about the new data.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
3.03 SEK | +1.00% | -3.81% | +6.32% |
07/05 | Medivir Aktiebolag Approves Board Appointments | CI |
30/04 | Transcript : Medivir AB, Q1 2024 Earnings Call, Apr 30, 2024 |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+6.32% | 31.14M | |
+2.97% | 108B | |
+10.21% | 105B | |
+1.57% | 23.46B | |
-12.77% | 21.72B | |
-7.05% | 18.64B | |
-37.64% | 17.45B | |
-6.50% | 17.19B | |
+6.00% | 13.99B | |
+37.20% | 12.53B |
- Stock Market
- Equities
- MVIR B Stock
- News Medivir AB
- Medivir Presents the First Clinical Data with Fostrox + Lenvima At the Asco GI Scientific Congress